An Israeli hypertension device that trains patients to breathe properly has been found by a new study to significantly lower blood pressure among diabetics, 80% of whom also have hypertension.
The US market alone for the device, called RESPeRATE and developed and marketed by the Israeli company InterCure, is estimated at 8m Americans who suffer from both diabetes and hypertension but do not reach goal blood pressure with weight loss, exercise or drugs.
An interim analysis of the results from the first 38 patients participating in a randomized controlled study of non-insulin-dependent diabetics with uncontrolled blood pressure was presented recently at the European General Practice Research Network meeting. The study, conducted by Dr. Moshe Schein from the Hadassah University Medical Center in Jerusalem’s Ein Kerem, compared the blood pressure response to eight weeks of 15-minute daily self-treatment with device-guided slow breathing using the RESPeRATE device with that of a control group that continued their usual care. Medicatio, diet and physical exercise were unchanged in both groups during the study.
Expulsion of air is stronger and slower. This reduces blood pressure, not only for the 15 minutes a day that the patient listens to the music from RESPeRATE, but long-term thereafter, said InterCure president and CEO Erez Gavish, who is based in Lod.
“This is fantastic news for the diabetes community and for InterCure. Diabetes treatment is all about self-care and empowerment and the RESPeRATE fits right in. The device is already used by more than 30,000 patients and doctors and I’m sure this study will accelerate the adoption of RESPeRATE in the diabetes community,” Gavish added. InterCure ( is a medical device company that creates and sells products that harness the therapeutic power of breathing for the treatment of hypertensio, heart failure, respiratory diseases and other conditions.
RESPeRATE ( is the only non-drug medical device indicated by the US Food and Drug Administration for the treatment of hypertension without drugs. RESPeRATE is now available in many countries, including Israel, the US, Australia and many in Europe.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…